Navigation Links
Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024
Date:9/1/2014

the pipeline, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry evolution.

All actual figures have been sourced and analysed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.

EXAMPLE HIGHLIGHTS

1. Driven by the sales of Adcetris and Kadcyla (the two drugs currently available commercially), the ADC market is likely to be worth more than USD 600 million in 2014.
2. About 45 molecules are currently in clinical development. Of these, approximately 25% are in Phase II or Phase III of development. As expected, the preclinical pipeline is also gradually expanding.
3. Most commonly used cytotoxins for ADCs under clinical development include auristatin, calicheamicin, maytansine and duocarmycin. Auristatin dominates the market and accounts for over 50% of ADCs in clinical development.
4. Roche, with 10 molecules in clinical development, has the most developed pipeline of ADCs. Relatively new entrants such as Oxford BioTherapeutics, Mersana Therapeutics, Abzena are likely to provide the necessary push (both in terms of technology and innovation).
5. Seattle Genetics and ImmunoGen are the two most active companies offering their proprietary ADC technologies to a large number of ADCs under development.
6. About 70%-80% of ADC manufacturing is currently outsourced. There are limited number of contract manufacturers with capabilities for development of linkers and cytotoxins. In addition, even fewer CMOs provide conjugation services for ADC.
7. Several technological developments have taken place in the recent past; more stable linkers and potent cytotoxins are likely to ensure that the next generation ADCs have improved safety/efficacy profile.
8. With around 7-10 new ADC commercial launches over the coming decade, we believe the overall mark
'/>"/>

SOURCE Reportlinker
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers
2. Spring Bioscience launches highly sensitive PD-L1 (SP142) antibody for immunotherapy research
3. Telik Receives $1.5 Million National Cancer Institute Contract to Develop Novel Antibody-based PET Imaging Agent for Pancreatic Cancer
4. Spring Bioscience launches highly sensitive PD-L1 (SP142) antibody, a component of Roches immunotherapy assay
5. Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody
6. FDA Grants Orphan Drug Designation for OncoSynergys Investigational Monoclonal Antibody OS2966 in the Treatment of Glioblastoma
7. EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma
8. Synthetic Biologics Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treating Whooping Cough (Pertussis) at Gordon Research Conference
9. Lilly Announces Acquisition of CGRP Antibody for Migraine Prevention from Arteaus Therapeutics
10. arGEN-X Starts Phase Ib Expansion Cohorts With ARGX-110, a Novel Anti-CD70 Antibody, in Cancer Patients
11. BioLineRx and JHL Biotech to Collaborate on Type 1 Diabetes Antibody Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) ... focus on Omega-3 therapies for cardiovascular disease (CVD) ... financial results for the fiscal year ended December ... in Canadian dollars unless otherwise stated. ... the right strategic partners and additional capitalization in ...
(Date:4/30/2015)... , April 30, 2015  Accuray Incorporated ... has signed an agreement with MIM Software Inc. ... TomoTherapy ® and CyberKnife ® product portfolios. ... and MIM technology. This is Accuray,s second collaboration ... development of the first iPad-based treatment plan review ...
(Date:4/30/2015)... , April 30, 2015  Thoratec Corporation (NASDAQ: ... support therapies to save, support and restore failing hearts, ... America Merrill Lynch 2015 Healthcare Conference on Thursday, May ... and Chief Executive Officer, will provide an update on ... (1:40 p.m., Eastern Daylight Time). The presentation ...
Breaking Medicine Technology:Pivotal Therapeutics Announces 2014 Financial Results 2Pivotal Therapeutics Announces 2014 Financial Results 3Pivotal Therapeutics Announces 2014 Financial Results 4Pivotal Therapeutics Announces 2014 Financial Results 5Pivotal Therapeutics Announces 2014 Financial Results 6Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 2Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 3Thoratec Presentation At Bank Of America Merrill Lynch Healthcare Conference To Be Webcast 2
... WELLINGTON , Fla., May 10 Dr. ... children with newly diagnosed type 1 diabetes for Protege Encore, ... second of two Phase III studies testing the safety and ... known as Protege, has completed enrollment of more than 530 ...
... Ireland , May 10 Warner Chilcott plc ... of America Merrill Lynch Healthcare Conference on Tuesday, May 11, 2010 ... be Paul Herendeen , Executive Vice President and Chief Financial Officer. , ... Warner Chilcott ,s presentation will be ...
Cached Medicine Technology:Protege Encore Clinical Trial Evaluates New Investigational Approach For Individuals Recently Diagnosed With Type 1 Diabetes 2
(Date:5/3/2015)... “ BolehVPN ” was featured on NewsWatch as part of ... technology products available to consumers. Scott Steinberg, a technology expert ... with viewers how to protect their private information. , A ... and even more so online. It helps everyone stay connected ... world. In terms of work, the internet makes things more ...
(Date:5/3/2015)... Mateo, CA (PRWEB) May 03, 2015 ... service, MnemeTherapy® at two upcoming area seminars. The first ... the PSA Annual Regional Stroke Conference to be held ... be offered on Wednesday, May 13 during the Dementia ... Plaza. , “These seminars offer an excellent opportunity ...
(Date:5/3/2015)... It is not too late to register to take ... of Lissa Anne Been in Arnold, Missouri on May 9, ... to honor her loving memory. It has benefited the renowned Brain ... turned 37, Lissa suffered a brain aneurysm . After two ... This event is designed to serve as a remembrance of her ...
(Date:5/2/2015)... As one of only 30 Illinois companies to ... Achievement and Recognition Program (SHARP) certification, Essentra Specialty ... Illinois Department of Labor to host this special event. ... by the Occupational Safety and Health Administration’s (“OSHA”) Onsite ... meet or exceed all of the necessary regulations and ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 Vancouver fencing company, ... now provide valuable advice to prospective clients related to their ... looking to install railings around their decks and patios. While ... questions that pop up once the person rolls up their ... of installing a railing in finding a gate that matches ...
Breaking Medicine News(10 mins):Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2
... & Full Year 2008 Earnings Conference Call , Thursday, February 12, ... Jan. 12 Cephalon, Inc . (Nasdaq: CEPH ... quarter and full year 2008 results for 5:00 p.m. EST on ... 4:10 p.m. EST Q4 & FY 2008 ...
... a sagging economy? Not necessarily the quick fix that you ... plastic surgeons.Recently, the U.S. Food and Drug Administration (FDA) gathered ... the use of dermal fillers. Although the injections have been ... (the creases running from the nose to the corners of ...
... Beginning Thursday, January 15, 2009, cosmetic surgeons from around ... Cosmetic Surgery,s 25th Anniversary Scientific Meeting to share and ... A Day Over Twenty-five" will be held from January ... Ridge Resort and Spa in Phoenix, Arizona.AACS continues its ...
... to study inherited susceptibility for skin cancer in mice. In the process, ... role in controlling this susceptibility. The technique, the scientists say, could ... ... January 12, 2009 -- UCSF researchers have used a new ...
... Steve Shulman to BoardHOUSTON, Jan. 12 Access ... of outsourced medical implantable device management solutions to ... board of directors has appointed board member Steve ... appointment following its second consecutive year of revenue ...
... of minimally invasive surgery procedures in operating theatres. However, ... much to be desired. Researcher Magdalena Chmarra has changed ... system which records and analyses the surgeon,s movements. As ... an objective benchmark for measuring a surgeon,s basic skills ...
Cached Medicine News:Health News:Dr. Sherrell Aston Addresses the Popularity of Dermal Fillers and Possible Long Term Side Effects 2Health News:The State of the Cosmetic Surgery Industry is Discussed at AACS 25th Anniversary Scientific Meeting 2Health News:UCSF Researchers Use New Tools to Move in on Cancer Susceptibility Genes 2Health News:UCSF Researchers Use New Tools to Move in on Cancer Susceptibility Genes 3Health News:UCSF Researchers Use New Tools to Move in on Cancer Susceptibility Genes 4Health News:Access MediQuip Appoints Former Priority Healthcare CEO to Chairman of the Board 2Health News:Access MediQuip Appoints Former Priority Healthcare CEO to Chairman of the Board 3Health News:New training method helps surgeons evaluate their own minimally invasive surgery skills 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: